Literature DB >> 31420823

Prescribing Associated with High-Risk Opioid Exposures Among Non-cancer Chronic Users of Opioid Analgesics: a Social Network Analysis.

Keiki Hinami1,2,3, Michael J Ray4,5, Kruti Doshi4,5, Maria Torres6, Steven Aks7, John J Shannon4, William E Trick4,5.   

Abstract

BACKGROUND: The continued rise in fatalities from opioid analgesics despite a steady decline in the number of individual prescriptions directing ≥ 90 morphine milligram equivalents (MME)/day may be explained by patient exposures to redundant prescriptions from multiple prescribers.
OBJECTIVES: We evaluated prescribers' specialty and social network characteristics associated with high-risk opioid exposures resulting from single-prescriber high-daily dose prescriptions or multi-prescriber discoordination.
DESIGN: Retrospective cohort study. PARTICIPANTS: A cohort of prescribers with opioid analgesic prescription claims for non-cancer chronic opioid users in an Illinois Medicaid managed care program in 2015-2016. MAIN MEASURES: Per prescriber rates of single-prescriber high-daily-dose prescriptions or multi-prescriber discoordination. KEY
RESULTS: For 2280 beneficiaries, 36,798 opioid prescription claims were submitted by 3532 prescribers. Compared to 3% of prescriptions (involving 6% of prescribers and 7% of beneficiaries) that directed ≥ 90 MME/day, discoordination accounted for a greater share of high-risk exposures-13% of prescriptions (involving 23% of prescribers and 24% of beneficiaries). The following specialties were at highest risk of discoordinated prescribing compared to internal medicine: dental (incident rate ratio (95% confidence interval) 5.9 (4.6, 7.5)), emergency medicine (4.7 (3.8, 5.8)), and surgical subspecialties (4.2 (3.0, 5.8)). Social network analysis identified 2 small interconnected prescriber communities of high-volume pain management specialists, and 3 sparsely connected groups of predominantly low-volume primary care or emergency medicine clinicians. Using multivariate models, we found that the sparsely connected sociometric positions were a risk factor for high-risk exposures.
CONCLUSION: Low-volume prescribers in the social network's periphery were at greater risk of intended or discoordinated prescribing than interconnected high-volume prescribers. Interventions addressing discoordination among low-volume opioid prescribers in non-integrated practices should be a priority. Demands for enhanced functionality and integration of Prescription Drug Monitoring Programs or referrals to specialized multidisciplinary pain management centers are potential policy implications.

Entities:  

Keywords:  Medicaid; care discoordination; epidemiology; harm reduction; opioid analgesic prescribing; social network analysis

Mesh:

Substances:

Year:  2019        PMID: 31420823      PMCID: PMC6848735          DOI: 10.1007/s11606-019-05114-3

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  23 in total

1.  Distribution of Opioids by Different Types of Medicare Prescribers.

Authors:  Jonathan H Chen; Keith Humphreys; Nigam H Shah; Anna Lembke
Journal:  JAMA Intern Med       Date:  2016-02       Impact factor: 21.873

Review 2.  What we know, and don't know, about the impact of state policy and systems-level interventions on prescription drug overdose.

Authors:  Tamara M Haegerich; Leonard J Paulozzi; Brian J Manns; Christopher M Jones
Journal:  Drug Alcohol Depend       Date:  2014-10-14       Impact factor: 4.492

Review 3.  Relationship between Nonmedical Prescription-Opioid Use and Heroin Use.

Authors:  Wilson M Compton; Christopher M Jones; Grant T Baldwin
Journal:  N Engl J Med       Date:  2016-01-14       Impact factor: 91.245

4.  Mandatory use of prescription drug monitoring programs.

Authors:  Rebecca L Haffajee; Anupam B Jena; Scott G Weiner
Journal:  JAMA       Date:  2015-03-03       Impact factor: 56.272

5.  Defining risk of prescription opioid overdose: pharmacy shopping and overlapping prescriptions among long-term opioid users in medicaid.

Authors:  Zhuo Yang; Barth Wilsey; Michele Bohm; Meghan Weyrich; Kakoli Roy; Dominique Ritley; Christopher Jones; Joy Melnikow
Journal:  J Pain       Date:  2015-02-11       Impact factor: 5.820

6.  Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival.

Authors:  M M Kitahata; T D Koepsell; R A Deyo; C L Maxwell; W T Dodge; E H Wagner
Journal:  N Engl J Med       Date:  1996-03-14       Impact factor: 91.245

7.  Associations between statewide prescription drug monitoring program (PDMP) requirement and physician patterns of prescribing opioid analgesics for patients with non-cancer chronic pain.

Authors:  Hsien-Chang Lin; Zhi Wang; Carol Boyd; Linda Simoni-Wastila; Anne Buu
Journal:  Addict Behav       Date:  2017-09-05       Impact factor: 3.913

8.  Association of Prescription Drug Monitoring Program Use With Opioid Prescribing and Health Outcomes: A Comparison of Program Users and Nonusers.

Authors:  Richard A Deyo; Sara E Hallvik; Christi Hildebran; Miguel Marino; Rachel Springer; Jessica M Irvine; Nicole O'Kane; Joshua Van Otterloo; Dagan A Wright; Gillian Leichtling; Lisa M Millet; Jody Carson; Wayne Wakeland; Dennis McCarty
Journal:  J Pain       Date:  2017-10-18       Impact factor: 5.820

9.  Relationship between high-risk patients receiving prescription opioids and high-volume opioid prescribers.

Authors:  Hsien-Yen Chang; Irene B Murimi; Christopher M Jones; G Caleb Alexander
Journal:  Addiction       Date:  2017-11-29       Impact factor: 6.526

Review 10.  Targeting practitioners: A review of guidelines, training, and policy in pain management.

Authors:  Kelly S Barth; Constance Guille; Jenna McCauley; Kathleen T Brady
Journal:  Drug Alcohol Depend       Date:  2017-04-01       Impact factor: 4.492

View more
  1 in total

1.  Barriers and facilitators to implementing changes in opioid prescribing in rural primary care clinics.

Authors:  Michael L Parchman; Brooke Ike; Katherine P Osterhage; Laura-Mae Baldwin; Kari A Stephens; Sarah Sutton
Journal:  J Clin Transl Sci       Date:  2020-01-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.